P2Y₁₂-inhibitor monotherapy after coronary stenting: are all P2Y₁₂-inhibitors equal?

References

• Cao D, Chandiramani R, Chiarito M, et al. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J. 2021 Jan 21;42(4):339–351.
   PubMedGoogle Scholar
• Knuuti J, Wijns W, Saraste A, et al. ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(3):407–477.
   Web of Science ®Google Scholar
• Collet J-P, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(37):3495–3497.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–177.
   Web of Science ®Google Scholar
• Piccolo R, Oliva A, Avvedimento M, et al. Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. EuroIntervention. 2021 Sep 20;17(7):550–560.
   PubMed Web of Science ®Google Scholar
• Giustino G, Mehran R, Dangas GD, et al. Characterization of the average daily ischemic and bleeding risk after primary PCI for STEMI. J Am Coll Cardiol. 2017 Oct 10;70(15):1846–1857.
   PubMedGoogle Scholar
• Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309–1320.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 4;371(23):2155–2166.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–1800.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Borghesi M, Tebaldi M, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013 Mar;34(12):909–919.
   PubMedGoogle Scholar
• Vranckx P, Valgimigli M, Juni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018 Sep 15;392(10151):940–949. London, England.
   PubMed Web of Science ®Google Scholar
• Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. Jama. 2019 Jun 25;321(24):2428–2437.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al., Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. Jama. 2019;321(24):2414–2427.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Morimoto T, Natsuaki M, et al., Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet Therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022;7(4):407.
   PubMed Web of Science ®Google Scholar
• Kim B-K, Hong S-J, Cho Y-H, et al., Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. Jama. 2020;323(23):2407–2416.
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019 Sep 26;381(21):2032–2042.
   PubMed Web of Science ®Google Scholar
• McClure JD, Ramsay JC, Berry C. Pooled analysis of bleeding, major adverse cardiovascular events, and all-cause mortality in clinical trials of time-constrained dual-antiplatelet therapy after percutaneous coronary intervention. J Am Heart Assoc. 2020 Aug 18;9(16):e017109.
   PubMedGoogle Scholar
• Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2020;42(4):308–319.
   Google Scholar
• Capodanno D, Mehran R, Valgimigli M, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018 Aug;15(8):480–496.
   PubMed Web of Science ®Google Scholar
• Verheugt FWA, Damman P, Damen SAJ, et al. P2Y12 blocker monotherapy after percutaneous coronary intervention. Neth Heart J. 2021 Nov;29(11):566–576.
   PubMedGoogle Scholar
• Ahmad S, Storey RF. Development and clinical use of prasugrel and ticagrelor. Curr Pharm Des. 2012;18(33):5240–5260.
   PubMedGoogle Scholar
• Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008 Aug 28;359(9):938–949.
   PubMed Web of Science ®Google Scholar
• Patrono C, García Rodríguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005 Dec 1;353(22):2373–2383.
   PubMed Web of Science ®Google Scholar
• Norgard NB, Abu-Fadel M. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag. 2009;5:873–882.
   PubMedGoogle Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521–1537.
   PubMed Web of Science ®Google Scholar
• Li S, Choi J-L, Guo LZ, et al. Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test. Ann Lab Med. 2016;36(1):42–48.
   PubMed Web of Science ®Google Scholar
• Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015 Jul 14;36(27):1762–1771.
   PubMed Web of Science ®Google Scholar
• Thomas MR, Storey RF. Genetics of response to antiplatelet therapy. Prog Mol Biol Transl Sci. 2014;124:123–153.
   PubMedGoogle Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363–375.
   PubMed Web of Science ®Google Scholar
• Lee CH, Franchi F, Angiolillo DJ. Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol. 2020 Nov;16(11):1079–1096.
   PubMed Web of Science ®Google Scholar
• Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016 Aug;22(8):939–947.
   PubMedGoogle Scholar
• Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008 Apr;48(4):475–484.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009 Apr;101(4):714–719.
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008 Jan 22;51(3):256–260.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19;374(9694):989–997. London, England
   PubMed Web of Science ®Google Scholar
• Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653.
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821–827.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11;363(20):1909–1917.
   PubMed Web of Science ®Google Scholar
• Bhavaraju K, Georgakis A, Jin J, et al. Antagonism of P2Y₁₂ reduces physiological thromboxane levels. Platelets. 2010;21(8):604–609.
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Dhanji AR, Tucker AT, et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost. 2010 Mar;8(3):613–615.
   PubMedGoogle Scholar
• Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol. 2012 Jun 12;59(24):2159–2164.
   PubMed Web of Science ®Google Scholar
• Winter M-P, Schneeweiss T, Cremer R, et al. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest. 2019;49(6):e13102–e13102.
   Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas J, et al. Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes: results of a randomized pharmacodynamic study in a feasibility investigation of rapid genetic testing. JACC Basic Transl Sci. 2020 May;5(5):419–428.
   PubMedGoogle Scholar
• Armstrong PC, Leadbeater PD, Chan MV, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011 Mar;9(3):552–561.
   PubMed Web of Science ®Google Scholar
• Vogel RF, Delewi R, Angiolillo DJ, et al. Pharmacodynamic effects of pre-hospital administered crushed prasugrel in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interventions. 2021 Jun 28;14(12):1323–1333.
   PubMedGoogle Scholar
• Montalescot G, Collet JP, Ecollan P, et al. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol. 2014 Dec 23;64(24):2563–2571.
   PubMed Web of Science ®Google Scholar
• Scudiero F, Canonico ME, Sanna GD, et al. Dual antiplatelet therapy with 3(rd) generation P2Y(12) inhibitors in STEMI patients: impact of body mass index on loading dose-response. Cardiovasc Drugs Ther. 2022 Feb 17. DOI:10.1007/s10557-022-07322-2.
   Google Scholar
• Ow KW, Parker WAE, Porter MM, et al. Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets. 2020 Oct 2;31(7):945–951.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Franchi F, Waksman R, et al. Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing Ad Hoc PCI. J Am Coll Cardiol. 2016 Feb 16;67(6):603–613.
   PubMed Web of Science ®Google Scholar
• Dehghani P, Lavoie A, Lavi S, et al. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. Am Heart J. 2017 Oct;192:105–112.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang P, Dong P, et al. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis. Coron Artery Dis. 2017 Nov;28(7):597–604.
   PubMedGoogle Scholar
• Wen M, Li Y, Qu X, et al. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord. 2020 Oct 01;20(1):430.
   PubMedGoogle Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012 Dec;5(6):797–804.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012 Jul 17;60(3):193–199.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Aggarwal N, et al. Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2016;134(11):780–792.
   PubMedGoogle Scholar
• Baber U, Zafar MU, Dangas G, et al. Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy. J Am Coll Cardiol. 2020 Feb 18;75(6):578–586.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Zwahlen M, Vranckx P, et al. Ticagrelor monotherapy or dual antiplatelet therapy after drug‐eluting stent implantation: per‐protocol analysis of the GLOBAL LEADERS trial. J Am Heart Assoc. 2022;11(10):e024291.
   PubMedGoogle Scholar
• Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2021;373:n1332.
   PubMed Web of Science ®Google Scholar
• Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011 Dec;32(23):2945–2953.
   PubMed Web of Science ®Google Scholar
• Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2015 Dec;4(6):555–560.
   PubMed Web of Science ®Google Scholar
• Zhang N, Xu W, Li O, et al. The risk of dyspnea in patients treated with third-generation P2Y(12) inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2020 Mar 17;20(1):140.
   PubMedGoogle Scholar
• Watanabe H, Morimoto T, Ogita M, et al. Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2. Cardiovasc Interv Ther. 2021 Oct;36(4):403–415.
   PubMedGoogle Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N Engl J Med. 2019 Oct 24;381(17):1621–1631.
   PubMed Web of Science ®Google Scholar
• Kogame N, Guimarães PO, Modolo R, et al. Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable cad: the aset pilot study. JACC Cardiovasc Interv. 2020 Oct 12;13(19):2251–2262.
   PubMedGoogle Scholar
• Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013 Oct;34(38):2940–2948.
   PubMed Web of Science ®Google Scholar
• Koo B-K, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021 Jun 26;397(10293):2487–2496.
   PubMedGoogle Scholar
• van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, et al. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J. 2021 Mar 7;42(10):1038–1046.
   PubMed Web of Science ®Google Scholar